Journal of Clinical Oncology via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Journal of Clinical Oncology' source. Wed, 08 Feb 2012 08:41:41 +0100 Cancer Health Disparities: Moving From Why They Occur to How They Can Be Prevented [EDITORIALS] http://www.medworm.com/index.php?rid=5666714&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F354%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5666714 Fri, 27 Jan 2012 05:00:00 +0100 5666714 Reply to P. Bohanes et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5638023&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F466%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638023 Fri, 27 Jan 2012 05:00:00 +0100 5638023 "HER Majesty's a Pretty Nice Girl but She Changes From Day to Day" [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5638022&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F465-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638022 Fri, 27 Jan 2012 05:00:00 +0100 5638022 Reply to F.L. Opdam et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5638021&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F465%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638021 Fri, 27 Jan 2012 05:00:00 +0100 5638021 Emphasizing the Value of Phenotyping in Patients Receiving Tamoxifen [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5638020&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F464%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638020 Fri, 27 Jan 2012 05:00:00 +0100 5638020 Reply to F. Ferrara [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5638019&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F463%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638019 Fri, 27 Jan 2012 05:00:00 +0100 5638019 Prediction of Early Death in Acute Myeloid Leukemia [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5638018&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F462%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638018 Fri, 27 Jan 2012 05:00:00 +0100 5638018 Reply to A. Kesikli et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5638017&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F461-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638017 Fri, 27 Jan 2012 05:00:00 +0100 5638017 Paclitaxel, Not Bevacizumab, Was Primarily Responsible for the Favorable Effects Seen in the RIBBON-2 Trial [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5638016&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F461%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638016 Fri, 27 Jan 2012 05:00:00 +0100 5638016 Reminders [ART OF ONCOLOGY] http://www.medworm.com/index.php?rid=5638015&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F459%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638015 Fri, 27 Jan 2012 05:00:00 +0100 5638015 Making Sense of Clinical Trial Data: Is Inverse Probability of Censoring Weighted Analysis the Answer to Crossover Bias? [STATISTICS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5638014&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F453%3Frss%3D1 Ideally, therapeutic interventions are evaluated through randomized clinical trials. These trials are commonly analyzed with an intent-to-treat (ITT) approach, whereby patients are analyzed in their assigned treatment group regardless of actual treatment received. If an interim analysis of such trials demonstrates compelling evidence of a difference in benefit, ethical considerations often dictate that the trial be unblinded and participants be provided access to the more efficacious agent. Because interim analysis may not address longer-term outcomes of interest, important clinical questions such as overall survival benefit—the ultimate test of efficacy to many—may remain unanswered. The ensuing crossover disturbs randomization and may lead to biased longer-term analysis, comp... Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638014 Fri, 27 Jan 2012 05:00:00 +0100 5638014 The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma [SPECIAL ARTICLE] http://www.medworm.com/index.php?rid=5638013&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F445%3Frss%3D1 Multiple myeloma (MM) is a remarkable example of rapid bench-to-bedside translation in new drug development. The proteasome inhibitor bortezomib and immunomodulatory drug lenalidomide targeted MM cells in the bone marrow (BM) microenvironment to overcome conventional drug resistance in laboratory and animal models and were rapidly translated into clinical trials demonstrating their efficacy in patients with relapsed and then newly diagnosed MM, with a doubling of the median survival as a direct result. The future is even brighter. First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell–dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysf... Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638013 Fri, 27 Jan 2012 05:00:00 +0100 5638013 Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword? [UNDERSTANDING THE PATHWAY] http://www.medworm.com/index.php?rid=5638012&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F441%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638012 Fri, 27 Jan 2012 05:00:00 +0100 5638012 Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer [Thoracic Oncology] http://www.medworm.com/index.php?rid=5638011&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F433%3Frss%3D1 Conclusion T790M may not be a rare event before or after TKI therapy in patients with NSCLC with EGFR-activating mutations. The pretreatment T790M mutation was associated with shorter PFS with EGFR TKI therapy in patients with NSCLC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638011 Fri, 27 Jan 2012 05:00:00 +0100 5638011 Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor [Pediatric Oncology] http://www.medworm.com/index.php?rid=5638010&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F426%3Frss%3D1 Conclusion GM-CSF–induced granulocyte activation in vivo is associated with improved patient outcome. This activation was more apparent when GM-CSF was given by the SC route instead of IV route. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638010 Fri, 27 Jan 2012 05:00:00 +0100 5638010 Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases [Neurooncology] http://www.medworm.com/index.php?rid=5638009&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F419%3Frss%3D1 Conclusion Prognostic factors for patients with brain metastases vary by diagnosis, and for each diagnosis, a robust separation into different GPA scores was discerned, implying considerable heterogeneity in outcome, even within a single tumor type. In summary, these indices and related worksheet provide an accurate and facile diagnosis-specific tool to estimate survival, potentially select appropriate treatment, and stratify clinical trials for patients with brain metastases. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638009 Fri, 27 Jan 2012 05:00:00 +0100 5638009 Health-Related Quality of Life Among 5-Year Survivors of Esophageal Cancer Surgery: A Prospective Population-Based Study [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5638008&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F413%3Frss%3D1 Conclusion HRQL recovers to a level comparable to that in the background population in most patients who survive 5 years after esophagectomy for cancer, although a subgroup of patients has substantially worse HRQL. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638008 Fri, 27 Jan 2012 05:00:00 +0100 5638008 Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5638007&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F406%3Frss%3D1 Conclusion Colon cancers from obese patients are less likely to show dMMR, suggesting obesity-related differences in the pathogenesis of colon cancer. Although obesity was independently associated with adverse outcome, the favorable prognostic impact of dMMR was maintained among obese patients. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638007 Fri, 27 Jan 2012 05:00:00 +0100 5638007 Racial Disparities in Stage-Specific Colorectal Cancer Mortality Rates From 1985 to 2008 [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5638006&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F401%3Frss%3D1 Conclusion The black-white disparities in CRC mortality increased for each stage of the disease, but the overall disparity in overall mortality was largely driven by trends for late-stage disease. Concerted efforts to prevent or detect CRC at earlier stages in blacks could improve the worsening black- white disparities. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638006 Fri, 27 Jan 2012 05:00:00 +0100 5638006 Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non-Small-Cell Lung Cancer [Palliative and Supportive Care] http://www.medworm.com/index.php?rid=5638005&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F394%3Frss%3D1 Conclusion Although patients with metastatic NSCLC received similar numbers of chemotherapy regimens in the sample, early palliative care optimized the timing of final chemotherapy administration and transition to hospice services, key measures of quality end-of-life care. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638005 Fri, 27 Jan 2012 05:00:00 +0100 5638005 Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (>= 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study [Hematologic Malignancies] http://www.medworm.com/index.php?rid=5638004&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F387%3Frss%3D1 Conclusion LDH level at diagnosis, mediastinal disease, and combined BM-positive/CNS-positive involvement are independent risk factors in children with mature B-cell NHL. Future studies should be developed to identify specific therapeutic strategies (immunotherapy) to overcome these risk factors and to identify the biologic basis associated with these prognostic factors in children with mature B-cell NHL. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638004 Fri, 27 Jan 2012 05:00:00 +0100 5638004 Distribution of Coronary Artery Stenosis After Radiation for Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=5638003&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F380%3Frss%3D1 Conclusion An increase of stenosis in mdLAD + dD in irradiated left-sided BC and an association between high-risk RT and stenosis in hotspot areas for radiation indicate a direct link between radiation and location of coronary stenoses. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638003 Fri, 27 Jan 2012 05:00:00 +0100 5638003 Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer [Gynecologic Cancer] http://www.medworm.com/index.php?rid=5638002&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F372%3Frss%3D1 Conclusion The efficacy of olaparib was consistent with previous studies. However, the efficacy of PLD was greater than expected. Olaparib 400 mg twice per day is a suitable dose to explore in further studies in this patient population. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638002 Fri, 27 Jan 2012 05:00:00 +0100 5638002 Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer [Gynecologic Cancer] http://www.medworm.com/index.php?rid=5638001&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F362%3Frss%3D1 Conclusion AMG 386 combined with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile. The data suggest evidence of antitumor activity and a dose-response effect, warranting further studies in ovarian cancer. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638001 Fri, 27 Jan 2012 05:00:00 +0100 5638001 Potential Utility of an Expression Array Signature for Predicting Anthracycline Responsiveness or Resistance [COMMENTS AND CONTROVERSIES] http://www.medworm.com/index.php?rid=5638000&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F357%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5638000 Fri, 27 Jan 2012 05:00:00 +0100 5638000 Cancer Heath Disparities: Moving From Why They Occur to How They Can Be Prevented [EDITORIALS] http://www.medworm.com/index.php?rid=5637999&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F354%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5637999 Fri, 27 Jan 2012 05:00:00 +0100 5637999 It Takes a Village [EDITORIALS] http://www.medworm.com/index.php?rid=5637998&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F353%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5637998 Fri, 27 Jan 2012 05:00:00 +0100 5637998 Breast Cancer Radiotherapy and Coronary Artery Stenosis: Location, Location, Location [EDITORIALS] http://www.medworm.com/index.php?rid=5637997&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F350%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5637997 Fri, 27 Jan 2012 05:00:00 +0100 5637997 Comparing Poly (ADP-Ribose) Polymerase Inhibitors With Standard Chemotherapy in BRCA-Mutated, Recurrent Ovarian Cancer: Lessons Learned From a Negative Trial [EDITORIALS] http://www.medworm.com/index.php?rid=5637996&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F347%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5637996 Fri, 27 Jan 2012 05:00:00 +0100 5637996 Moving Beyond Anti-Vascular Endothelial Growth Factor Therapy in Ovarian Cancer [EDITORIALS] http://www.medworm.com/index.php?rid=5637995&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2F345%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5637995 Fri, 27 Jan 2012 05:00:00 +0100 5637995 Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5637994&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2Fe45%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5637994 Fri, 27 Jan 2012 05:00:00 +0100 5637994 Sudden Death Related to Toxicity in a Patient on Capecitabine and Irinotecan Plus Bevacizumab Intake: Pharmacogenetic Implications [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5637993&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2Fe41%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5637993 Fri, 27 Jan 2012 05:00:00 +0100 5637993 Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5637992&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F4%2Fe37%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5637992 Fri, 27 Jan 2012 05:00:00 +0100 5637992 Author Correction [CORRECTIONS] http://www.medworm.com/index.php?rid=5608086&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F343-b%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608086 Wed, 18 Jan 2012 05:00:00 +0100 5608086 Reply to N. Chen et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608083&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F341%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608083 Wed, 18 Jan 2012 05:00:00 +0100 5608083 Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608082&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F340%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608082 Wed, 18 Jan 2012 05:00:00 +0100 5608082 Reply to O. Dizdar et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608081&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F339-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608081 Wed, 18 Jan 2012 05:00:00 +0100 5608081 p53 Status in Locally Advanced Bladder Cancer [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608080&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F339%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608080 Wed, 18 Jan 2012 05:00:00 +0100 5608080 Reply to J.W. Locasale et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608079&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F338%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608079 Wed, 18 Jan 2012 05:00:00 +0100 5608079 Maximizing the Efficacy of Angiogenesis Inhibitors [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608078&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F337%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608078 Wed, 18 Jan 2012 05:00:00 +0100 5608078 Reply to L. Wannesson et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608077&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F336-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608077 Wed, 18 Jan 2012 05:00:00 +0100 5608077 Concordant and Discordant Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma: Are They Understudied Phenomena? [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608076&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F336%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608076 Wed, 18 Jan 2012 05:00:00 +0100 5608076 Reply to Y. Pointreau et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608075&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F335%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608075 Wed, 18 Jan 2012 05:00:00 +0100 5608075 Fatal Infusion Reactions to Cetuximab: Role of Immunoglobulin E-Mediated Anaphylaxis [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5608074&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F334%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608074 Wed, 18 Jan 2012 05:00:00 +0100 5608074 Phosphatidylinositide-3-Kinase Inhibitors: Addressing Questions of Isoform Selectivity and Pharmacodynamic/Predictive Biomarkers in Early Clinical Trials [UNDERSTANDING THE PATHWAY] http://www.medworm.com/index.php?rid=5608073&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F331%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608073 Wed, 18 Jan 2012 05:00:00 +0100 5608073 Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern? [UNDERSTANDING THE PATHWAY] http://www.medworm.com/index.php?rid=5608072&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F329%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608072 Wed, 18 Jan 2012 05:00:00 +0100 5608072 Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma [Melanoma] http://www.medworm.com/index.php?rid=5608071&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F322%3Frss%3D1 Conclusion HDI can be administered combined with tremelimumab with acceptable toxicity and promising durable antitumor efficacy that warrant further testing in a randomized trial. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608071 Wed, 18 Jan 2012 05:00:00 +0100 5608071 RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors [Translational Oncology] http://www.medworm.com/index.php?rid=5608070&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F316%3Frss%3D1 Conclusion Squamous cell tumors from patients treated with an RAF inhibitor have a distinct mutational profile that supports a mechanism of therapy-induced tumorigenesis in RAS-primed cells. Conceivably, cotargeting of MEK together with RAF may reduce or prevent formation of these tumors. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608070 Wed, 18 Jan 2012 05:00:00 +0100 5608070 Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications [Sarcomas] http://www.medworm.com/index.php?rid=5608069&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F308%3Frss%3D1 Conclusion Because ALK aberrations on genomic and protein levels are frequently found in RMSs, in particular ARMS, and are associated with disease progression and outcome in ERMS, ALK may play a role in tumor biology and may provide a potential therapeutic target for these tumors. Future research should aim at the oncogenic role of ALK and the potential effect of ALK inhibitors in RMS. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608069 Wed, 18 Jan 2012 05:00:00 +0100 5608069 Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer [Urologic Oncology] http://www.medworm.com/index.php?rid=5608068&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F300%3Frss%3D1 Conclusion Here we document a significant relationship between increasing levels of residual serum platinum and NTX severity after adjusting for initial cisplatin dose. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608068 Wed, 18 Jan 2012 05:00:00 +0100 5608068 Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study [Hematologic Malignancies] http://www.medworm.com/index.php?rid=5608067&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F291%3Frss%3D1 Conclusion Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608067 Wed, 18 Jan 2012 05:00:00 +0100 5608067 Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors [Phase I and Clinical Pharmacology] http://www.medworm.com/index.php?rid=5608066&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F282%3Frss%3D1 Conclusion This study demonstrates feasibility and proof-of-concept of class I PI3K inhibition in patients with advanced cancers. BKM120, at the MTD of 100 mg/d, is safe and well tolerated, with a favorable PK profile, clear evidence of target inhibition, and preliminary antitumor activity. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608066 Wed, 18 Jan 2012 05:00:00 +0100 5608066 Longitudinal Assessment of Chemotherapy-Induced Structural Changes in Cerebral White Matter and Its Correlation With Impaired Cognitive Functioning [Breast Cancer] http://www.medworm.com/index.php?rid=5608065&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F274%3Frss%3D1 Conclusion We report evidence of longitudinal changes in cognitive functioning and cerebral WM integrity after chemotherapy as well as an association between both. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608065 Wed, 18 Jan 2012 05:00:00 +0100 5608065 Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5608064&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F268%3Frss%3D1 Conclusion The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in gastric cancer. A subsequent trial (ARTIST-II) in patients with lymph node–positive gastric cancer is planned. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608064 Wed, 18 Jan 2012 05:00:00 +0100 5608064 Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5608063&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F263%3Frss%3D1 Conclusion pcCRC is associated with a significantly shorter OS and PFS as compared with other manifestations of mCRC. Future trials for mCRC should consider stratifying on the basis of pcCRC status. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608063 Wed, 18 Jan 2012 05:00:00 +0100 5608063 Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group [Pediatric Oncology] http://www.medworm.com/index.php?rid=5608062&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F256%3Frss%3D1 Conclusion Cixutumumab is well tolerated in children with refractory solid tumors. The recommended phase II dose is 9 mg/kg. Limited single-agent activity of cixutumumab was seen in ES. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608062 Wed, 18 Jan 2012 05:00:00 +0100 5608062 Risk Factors for Obesity in Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study [Pediatric Oncology] http://www.medworm.com/index.php?rid=5608061&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F246%3Frss%3D1 Conclusion Treatment, lifestyle, and intrapersonal factors, as well as the use of specific antidepressants, may contribute to obesity among survivors. A multifaceted intervention, including alternative drug and other therapies for depression and anxiety, may be required to reduce risk. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608061 Wed, 18 Jan 2012 05:00:00 +0100 5608061 Congenital Anomalies in the Children of Cancer Survivors: A Report From the Childhood Cancer Survivor Study [Pediatric Oncology] http://www.medworm.com/index.php?rid=5608060&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F239%3Frss%3D1 Conclusion Our findings offer strong evidence that the children of cancer survivors are not at significantly increased risk for congenital anomalies stemming from their parent's exposure to mutagenic cancer treatments. This information is important for counseling cancer survivors planning to have children. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608060 Wed, 18 Jan 2012 05:00:00 +0100 5608060 Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors [Rapid Communication] http://www.medworm.com/index.php?rid=5608059&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F232%3Frss%3D1 Conclusion A single measurement of BCR-ABL1 transcripts performed at 3 months is the best way to identify patients destined to fare poorly, thereby allowing early clinical intervention. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608059 Wed, 18 Jan 2012 05:00:00 +0100 5608059 "Doctor, Will the Treatment You Are Recommending Cause Chemobrain?" [EDITORIALS] http://www.medworm.com/index.php?rid=5608058&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F229%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608058 Wed, 18 Jan 2012 05:00:00 +0100 5608058 Factors Dictating Outcomes in Patients With Colorectal Cancer and Peritoneal Carcinomatosis: Selection, Resection, or Convection? [EDITORIALS] http://www.medworm.com/index.php?rid=5608057&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F226%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608057 Wed, 18 Jan 2012 05:00:00 +0100 5608057 Does Cancer Treatment in Childhood Induce Transgenerational Genetic Damage? [EDITORIALS] http://www.medworm.com/index.php?rid=5608056&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F225%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608056 Wed, 18 Jan 2012 05:00:00 +0100 5608056 Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia [EDITORIALS] http://www.medworm.com/index.php?rid=5608055&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2F223%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608055 Wed, 18 Jan 2012 05:00:00 +0100 5608055 Acute Leukemic Manifestation of Recurrent Anaplastic Large-Cell Lymphoma 20 Years After Autologous Bone Marrow Transplantation [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5608054&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2Fe34%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608054 Wed, 18 Jan 2012 05:00:00 +0100 5608054 Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5608053&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2Fe30%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608053 Wed, 18 Jan 2012 05:00:00 +0100 5608053 Scleromyxedema: A Cutaneous Paraneoplastic Syndrome Associated With Thymic Carcinoma [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5608052&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2Fe27%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608052 Wed, 18 Jan 2012 05:00:00 +0100 5608052 Spontaneous Regression of Follicular Dendritic Cell Sarcoma [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5608051&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F3%2Fe24%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5608051 Wed, 18 Jan 2012 05:00:00 +0100 5608051 Reply to M. Keyhani and N. Mahmoudi [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5571909&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F220%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571909 Fri, 06 Jan 2012 05:00:00 +0100 5571909 Research on Acute Promyelocytic Leukemia Conducted in Iran [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5571906&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F217-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571906 Fri, 06 Jan 2012 05:00:00 +0100 5571906 Use of Arsenic Trioxide As a First-Line Single Agent in the Treatment of Acute Promyelocytic Leukemia [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5571905&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F217%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571905 Fri, 06 Jan 2012 05:00:00 +0100 5571905 Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic Review [STATISTICS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5571904&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F210%3Frss%3D1 Conclusion The rates of trial registration and of trials with clearly defined PEPs have improved over time; however, 14% of these trials reported a different PEP in the final publication. Intrapublication inconsistencies in PEP reporting are frequent. Our findings highlight the need for investigators, peer reviewers, and readers to exercise increased awareness and scrutiny of reporting outcomes of oncology RCTs. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571904 Fri, 06 Jan 2012 05:00:00 +0100 5571904 The Challenge and Promise of the Genomic Era [SPECIAL ARTICLE] http://www.medworm.com/index.php?rid=5571903&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F203%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571903 Fri, 06 Jan 2012 05:00:00 +0100 5571903 Completing the Arc: Targeted Inhibition of RET in Medullary Thyroid Cancer [UNDERSTANDING THE PATHWAY] http://www.medworm.com/index.php?rid=5571902&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F200%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571902 Fri, 06 Jan 2012 05:00:00 +0100 5571902 Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 [Urologic Oncology] http://www.medworm.com/index.php?rid=5571901&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F191%3Frss%3D1 Conclusion There were no significant differences in efficacy between the two treatment groups. The incidence of severe acute toxicities was higher for those receiving M-CAVI. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571901 Fri, 06 Jan 2012 05:00:00 +0100 5571901 Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab [Hematologic Malignancies] http://www.medworm.com/index.php?rid=5571900&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F184%3Frss%3D1 Conclusion An early PET scan after two cycles of treatment can effectively predict the outcome in patients with DLBCL treated with rituximab and anthracycline-based chemotherapy by using either a visual or quantitative approach. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571900 Fri, 06 Jan 2012 05:00:00 +0100 5571900 Familial Aggregation of Acute Myeloid Leukemia and Myelodysplastic Syndromes [Hematologic Malignancies] http://www.medworm.com/index.php?rid=5571899&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F179%3Frss%3D1 Conclusion We did not find evidence for familial aggregation of the severe end of the spectrum of myeloid malignancies (AML and MDS). The risks of myeloproliferative neoplasms were modestly increased with trends toward significance, suggesting a possible role of inheritance. In contrast, although limited in sample size, relatives of young patients with AML were at increased risk of AML/MDS, suggesting that germline genes may play a stronger role in these patients. The increased risk of all hematologic malignancies and of solid tumors among relatives of patients with AML suggests that genes for malignancy in general and/or other environmental factors may be shared. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571899 Fri, 06 Jan 2012 05:00:00 +0100 5571899 Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer [Thoracic Oncology] http://www.medworm.com/index.php?rid=5571898&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F172%3Frss%3D1 Conclusion Although the study was terminated early, preoperative gemcitabine plus cisplatin followed by radical surgery improved survival in patients with clinical stage IIB/IIIA NSCLC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571898 Fri, 06 Jan 2012 05:00:00 +0100 5571898 Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations [Breast Cancer] http://www.medworm.com/index.php?rid=5571897&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F164%3Frss%3D1 Conclusion Baseline insulin- and obesity-related variables exert different patterns of prognostic associations over time in early BC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571897 Fri, 06 Jan 2012 05:00:00 +0100 5571897 Breast Cancer Survivors' Perceptions of Survivorship Care Options [Breast Cancer] http://www.medworm.com/index.php?rid=5571896&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F158%3Frss%3D1 Conclusion Breast cancer survivors are comfortable with both PCPs and NPs providing follow-up care, although they indicate a preference for medical oncologists. Given patients' negative impressions of a virtual visit, increased familiarity with and research investigating this emerging concept are needed. The NP-led survivorship clinic model, with increased guidance for PCPs, offers a promising route for improving quality of and satisfaction with survivor care. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571896 Fri, 06 Jan 2012 05:00:00 +0100 5571896 Prognostic Effect of Circulating Adiponectin in a Randomized 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=5571895&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F151%3Frss%3D1 Conclusion Low adiponectin levels are associated with a history of prior intraepithelial neoplasia or pT1mic/pT1a breast cancer and higher risk of second breast neoplastic events in premenopausal women. The associations are independent of BMI, mammographic density, and treatment. Our findings support the role of adiponectin as a potential target for premenopausal breast cancer prevention and treatment. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571895 Fri, 06 Jan 2012 05:00:00 +0100 5571895 Influence of Race, Insurance, Socioeconomic Status, and Hospital Type on Receipt of Guideline-Concordant Adjuvant Systemic Therapy for Locoregional Breast Cancers [Breast Cancer] http://www.medworm.com/index.php?rid=5571894&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F142%3Frss%3D1 Conclusion Sociodemographic and hospital factors are associated with guideline-concordant use of systemic therapy for breast cancer. The identification of modifiable factors that lead to nonguideline treatment may reduce disparities in breast cancer survival. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571894 Fri, 06 Jan 2012 05:00:00 +0100 5571894 Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial [Head and Neck Cancer] http://www.medworm.com/index.php?rid=5571893&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F134%3Frss%3D1 Conclusion Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761). (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571893 Fri, 06 Jan 2012 05:00:00 +0100 5571893 Evolution of Clinical Trials Registries [EDITORIALS] http://www.medworm.com/index.php?rid=5571892&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F131%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571892 Fri, 06 Jan 2012 05:00:00 +0100 5571892 Induction Chemotherapy and Surgery for Early-Stage Non-Small-Cell Lung Cancer: What Have We Learned From Randomized Trials? [EDITORIALS] http://www.medworm.com/index.php?rid=5571891&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F128%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571891 Fri, 06 Jan 2012 05:00:00 +0100 5571891 Obesity and Breast Cancer Outcome: Adding to the Evidence [EDITORIALS] http://www.medworm.com/index.php?rid=5571890&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F126%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571890 Fri, 06 Jan 2012 05:00:00 +0100 5571890 Adiponectin: A Risk Biomarker and Attractive Target for Chemoprevention [EDITORIALS] http://www.medworm.com/index.php?rid=5571889&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F124%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571889 Fri, 06 Jan 2012 05:00:00 +0100 5571889 Role of Nonclinical Factors in the Receipt of High-Quality Systemic Adjuvant Breast Cancer Treatment [EDITORIALS] http://www.medworm.com/index.php?rid=5571888&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F121%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571888 Fri, 06 Jan 2012 05:00:00 +0100 5571888 Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer [EDITORIALS] http://www.medworm.com/index.php?rid=5571887&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2F119%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571887 Fri, 06 Jan 2012 05:00:00 +0100 5571887 Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid Cancer [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5571886&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2Fe21%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571886 Fri, 06 Jan 2012 05:00:00 +0100 5571886 Cerebral Sinus Thrombosis and Leptomeningeal Carcinomatosis in a Patient With Ovarian Cancer [DIGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5571885&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2Fe19%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571885 Fri, 06 Jan 2012 05:00:00 +0100 5571885 Multimodal Therapy of an Intramedullary Cervical Primitive Neuroectodermal Tumor in an Adult [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5571884&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2Fe15%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571884 Fri, 06 Jan 2012 05:00:00 +0100 5571884 Takotsubo Cardiomyopathy and Fluorouracil: Case Report and Review of the Literature [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5571883&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2Fe11%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571883 Fri, 06 Jan 2012 05:00:00 +0100 5571883 Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5571882&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2Fe7%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571882 Fri, 06 Jan 2012 05:00:00 +0100 5571882 Cervical Adenocarcinoma in a Patient With Lynch Syndrome, Muir-Torre Variant [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5571881&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F2%2Fe5%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5571881 Fri, 06 Jan 2012 05:00:00 +0100 5571881 Reply to E.M. Gilles [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5551996&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F117%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551996 Thu, 29 Dec 2011 05:00:00 +0100 5551996 Radiologic Reviews: More Second Guessing From Armchairs Cannot Lead the Way [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5551995&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F116%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551995 Thu, 29 Dec 2011 05:00:00 +0100 5551995 Reply to L.V. dos Santos et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5551994&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F115%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551994 Thu, 29 Dec 2011 05:00:00 +0100 5551994 FOLFIRINOX: A Great Leap Forward, but for Whom? [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5551993&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F114-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551993 Thu, 29 Dec 2011 05:00:00 +0100 5551993 Reply to C.B. Simone II [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5551992&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F114%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551992 Thu, 29 Dec 2011 05:00:00 +0100 5551992 Secondary Abdominal-Pelvic Malignancies Attributable to Diagnostic Radiation Exposure in Patients With Testicular Malignancies [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5551991&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F113%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551991 Thu, 29 Dec 2011 05:00:00 +0100 5551991 More Than Just an Oncogene Translocation and a Kinase Inhibitor: Kevin's Story [ART OF ONCOLOGY] http://www.medworm.com/index.php?rid=5551990&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F110%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551990 Thu, 29 Dec 2011 05:00:00 +0100 5551990 Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology [ASCO SPECIAL ARTICLE] http://www.medworm.com/index.php?rid=5551989&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F88%3Frss%3D1 A MESSAGE FROM ASCO'S PRESIDENT It has been forty years since President Richard Nixon signed the National Cancer Act of 1971, which many view as the nation's declaration of the "War on Cancer." The bill has led to major investments in cancer research and significant increases in cancer survival. Today, two-thirds of patients survive at least five years after being diagnosed with cancer compared with just half of all diagnosed patients surviving five years after diagnosis in 1975. The research advances detailed in this year's Clinical Cancer Advances demonstrate that improvements in cancer screening, treatment, and prevention save and improve lives. But although much progress has been made, cancer remains one of the world's most serious health problems. In the United States, the disease is ... Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551989 Thu, 29 Dec 2011 05:00:00 +0100 5551989 From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of Rapamycin [UNDERSTANDING THE PATHWAY] http://www.medworm.com/index.php?rid=5551988&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F85%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551988 Thu, 29 Dec 2011 05:00:00 +0100 5551988 Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas [Sarcomas] http://www.medworm.com/index.php?rid=5551987&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F78%3Frss%3D1 Conclusion Single-agent ridaforolimus in patients with advanced and pretreated sarcomas led to PFS results that compare favorably with historical metrics. A phase III trial based on these data will further define ridaforolimus activity in sarcomas. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551987 Thu, 29 Dec 2011 05:00:00 +0100 5551987 Nonmalignant Late Effects and Compromised Functional Status in Survivors of Hematopoietic Cell Transplantation [Hematologic Malignancies] http://www.medworm.com/index.php?rid=5551986&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F71%3Frss%3D1 Conclusion The burden of nonmalignant late effects after HCT is high, even with modern treatments and relatively short follow-up. These late effects are associated with poor health and functional status, underscoring the need for close follow-up of this group and additional research to address these complications. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551986 Thu, 29 Dec 2011 05:00:00 +0100 5551986 Molecular Detection of Tumor Cells in Regional Lymph Nodes Is Associated With Disease Recurrence and Poor Survival in Node-Negative Colorectal Cancer: A Systematic Review and Meta-Analysis [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5551985&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F60%3Frss%3D1 Conclusion Molecular detection of occult disease in regional lymph nodes is associated with an increased risk of disease recurrence and poor survival in patients with node-negative CRC. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551985 Thu, 29 Dec 2011 05:00:00 +0100 5551985 Impact of Diabetes Mellitus and Insulin Use on Survival After Colorectal Cancer Diagnosis: The Cancer Prevention Study-II Nutrition Cohort [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5551984&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F53%3Frss%3D1 Conclusion Patients with CRC and T2DM have a higher risk of mortality than patients with CRC who do not have T2DM, especially a higher risk of death from CVD. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551984 Thu, 29 Dec 2011 05:00:00 +0100 5551984 Impact of Body Mass Index on Survival After Colorectal Cancer Diagnosis: The Cancer Prevention Study-II Nutrition Cohort [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5551983&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F42%3Frss%3D1 Conclusion This study suggests that prediagnosis BMI, but not postdiagnosis BMI, is an important predictor of survival among patients with nonmetastatic colorectal cancer. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551983 Thu, 29 Dec 2011 05:00:00 +0100 5551983 BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma [Melanoma] http://www.medworm.com/index.php?rid=5551982&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F34%3Frss%3D1 Conclusion The study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551982 Thu, 29 Dec 2011 05:00:00 +0100 5551982 Genetic Disease in the Children of Danish Survivors of Childhood and Adolescent Cancer [Pediatric Oncology] http://www.medworm.com/index.php?rid=5551981&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F27%3Frss%3D1 Conclusion Mutagenic chemotherapy and radiotherapy doses to the gonads were not associated with genetic defects in children of cancer survivors. However, larger studies need to be conducted to further explore potential associations between high-dose pelvic irradiation and specific adverse pregnancy outcomes. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551981 Thu, 29 Dec 2011 05:00:00 +0100 5551981 Breast Cancer Prognosis in BRCA1 and BRCA2 Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study [Breast Cancer] http://www.medworm.com/index.php?rid=5551980&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F19%3Frss%3D1 Conclusion Outcomes of BRCA1 mutation carriers were similar to those of patients with sporadic breast cancer. Worse outcomes in BRCA2 mutation carriers in univariable analysis seem to reflect the presence of more adverse tumor characteristics in these carriers. Similar outcomes were identified in BRCA2 carriers and those with sporadic disease in multivariable analyses. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551980 Thu, 29 Dec 2011 05:00:00 +0100 5551980 Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial [Breast Cancer] http://www.medworm.com/index.php?rid=5551979&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F11%3Frss%3D1 Conclusion Integration of capecitabine into a regimen that contains docetaxel, epirubicin, and cyclophosphamide did not improve RFS significantly compared with a similar regimen without capecitabine. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551979 Thu, 29 Dec 2011 05:00:00 +0100 5551979 Energy in and Energy out: What Matters for Survivors of Colorectal Cancer? [EDITORIALS] http://www.medworm.com/index.php?rid=5551978&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F7%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551978 Thu, 29 Dec 2011 05:00:00 +0100 5551978 BEAM Trial: Lighting the Way Ahead? [EDITORIALS] http://www.medworm.com/index.php?rid=5551977&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F6%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551977 Thu, 29 Dec 2011 05:00:00 +0100 5551977 Diffuse Osteosclerosis-Associated Acute Myeloid Leukemia [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5551976&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2Fe3%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551976 Thu, 29 Dec 2011 05:00:00 +0100 5551976 Optimizing Reproductive Outcome in Children and Young People With Cancer [EDITORIALS] http://www.medworm.com/index.php?rid=5551975&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F3%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551975 Thu, 29 Dec 2011 05:00:00 +0100 5551975 Should All Women With Breast Cancer Be Tested for BRCA Mutations at the Time of Diagnosis? [EDITORIALS] http://www.medworm.com/index.php?rid=5551974&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F2%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551974 Thu, 29 Dec 2011 05:00:00 +0100 5551974 Acute Isolated Transmural Neutropenic Gastritis [DIAGNOSIS IN ONCOLOGY] http://www.medworm.com/index.php?rid=5551973&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2Fe1%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551973 Thu, 29 Dec 2011 05:00:00 +0100 5551973 Reporting of Adjuvant Breast Cancer Trials: When Is the Right Time? [EDITORIALS] http://www.medworm.com/index.php?rid=5551972&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F30%2F1%2F1%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5551972 Thu, 29 Dec 2011 05:00:00 +0100 5551972 Journal Correction [Corrections] http://www.medworm.com/index.php?rid=5515027&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4847-c%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515027 Fri, 16 Dec 2011 05:00:00 +0100 5515027 Idiotype Vaccination As Consolidation Therapy: Time for Integration Into Standard of Care for Follicular Lymphoma? [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5515023&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4845-a%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515023 Fri, 16 Dec 2011 05:00:00 +0100 5515023 Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical Cancer [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5515022&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4845%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515022 Fri, 16 Dec 2011 05:00:00 +0100 5515022 Reply to H. Starz et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5515021&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4844%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515021 Fri, 16 Dec 2011 05:00:00 +0100 5515021 Tumor Penetrative Depth Considers Both the Size of Sentinel Lymph Node Metastases and Their Location in Relation to the Nodal Capsule [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5515020&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4843%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515020 Fri, 16 Dec 2011 05:00:00 +0100 5515020 Reply to R. Tibes et al [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5515019&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4842%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515019 Fri, 16 Dec 2011 05:00:00 +0100 5515019 Activity of Alemtuzumab in Acute Myelogenous Leukemia and Myelodysplastic Syndrome With Chromosome 7 Aberrations [CORRESPONDENCE] http://www.medworm.com/index.php?rid=5515018&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4841%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515018 Fri, 16 Dec 2011 05:00:00 +0100 5515018 "Doc, Please Don't Tell My Wife..." [ART OF ONCOLOGY] http://www.medworm.com/index.php?rid=5515017&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4839%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515017 Fri, 16 Dec 2011 05:00:00 +0100 5515017 MET Signaling Pathway: A Rational Target for Cancer Therapy [UNDERSTANDING THE PATHWAY] http://www.medworm.com/index.php?rid=5515016&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4837%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515016 Fri, 16 Dec 2011 05:00:00 +0100 5515016 Cancer Immunotherapy Comes of Age [BIOLOGY OF NEOPLASIA] http://www.medworm.com/index.php?rid=5515015&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4828%3Frss%3D1 Cancer immunotherapy comprises a variety of treatment approaches, incorporating the tremendous specificity of the adaptive immune system (T cells and antibodies) as well as the diverse and potent cytotoxic weaponry of both adaptive and innate immunity. Immunotherapy strategies include antitumor monoclonal antibodies, cancer vaccines, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate immune cells or block immune inhibitory pathways (so-called immune checkpoints). Although clear clinical efficacy has been demonstrated with antitumor antibodies since the late 1990s, other immunotherapies had not been shown to be effective until recently, when a spate of successes established the broad potential o... Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515015 Fri, 16 Dec 2011 05:00:00 +0100 5515015 Thymic Malignancies: From Clinical Management to Targeted Therapies [REVIEW ARTICLE] http://www.medworm.com/index.php?rid=5515014&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4820%3Frss%3D1 Conclusion Drug development for the treatment of thymic malignancies is difficult because of the rarity of these tumors. Ethnic differences are becoming apparent, with aggressive subtypes being observed in Asians and African Americans. Incremental improvements in our understanding of tumor biology suggest that molecular profiling–directed therapies may be the preferred route of investigation in the future. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515014 Fri, 16 Dec 2011 05:00:00 +0100 5515014 Use of a Decision Aid to Help Caregivers Discuss Terminal Disease Status With a Family Member With Cancer: A Randomized Controlled Trial [Palliative and Supportive Care] http://www.medworm.com/index.php?rid=5515013&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4811%3Frss%3D1 Conclusion Decision aids can help caregivers, with the aid of trained professionals, to communicate with patients about their terminal illness. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515013 Fri, 16 Dec 2011 05:00:00 +0100 5515013 MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5515012&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4803%3Frss%3D1 Conclusion MET amplification defines a small and aggressive subset of GEC with indications of transient sensitivity to the targeted MET inhibitor crizotinib (PF-02341066). (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515012 Fri, 16 Dec 2011 05:00:00 +0100 5515012 Predicting Survival After Curative Colectomy for Cancer: Individualizing Colon Cancer Staging [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5515011&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4796%3Frss%3D1 Conclusion Prognostic models incorporating readily available data elements outperform the current AJCC system. These models can assist in personalizing treatment and follow-up for patients with colon cancer. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515011 Fri, 16 Dec 2011 05:00:00 +0100 5515011 Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5515010&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4789%3Frss%3D1 Conclusion In this study, qPCR revealed approximately 10% of white patients with gastric cancer harboring MET CNG of five or more copies. This marker was significantly associated with unfavorable prognosis. This information is relevant to the current clinical development of anti-MET compounds. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515010 Fri, 16 Dec 2011 05:00:00 +0100 5515010 Plasma MicroRNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma [Gastrointestinal Cancer] http://www.medworm.com/index.php?rid=5515009&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4781%3Frss%3D1 Conclusion We found a plasma microRNA panel that has considerable clinical value in diagnosing early-stage HCC. Thus, patients who would have otherwise missed the curative treatment window can benefit from optimal therapy. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515009 Fri, 16 Dec 2011 05:00:00 +0100 5515009 Growth Hormone Secretion After Conformal Radiation Therapy in Pediatric Patients With Localized Brain Tumors [Pediatric Oncology] http://www.medworm.com/index.php?rid=5515008&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4776%3Frss%3D1 Conclusion GH secretion after CRT can be predicted on the basis of dose and time after irradiation in pediatric patients with localized brain tumors. These findings provide an objective radiation dose constraint for the hypothalamus. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515008 Fri, 16 Dec 2011 05:00:00 +0100 5515008 Medical Oncologists' Attitudes and Practice in Cancer Pain Management: A National Survey [Clinical Practice] http://www.medworm.com/index.php?rid=5515007&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4769%3Frss%3D1 Conclusion These data suggest that, for more than 20 years, a focus on cancer pain has not adequately addressed the perception of treatment barriers or limitations in pain-related knowledge and practice within the oncology community. Additional efforts are needed to achieve meaningful progress. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515007 Fri, 16 Dec 2011 05:00:00 +0100 5515007 A Case-Match Study Comparing Unilateral With Synchronous Bilateral Breast Cancer Outcomes [Breast Cancer] http://www.medworm.com/index.php?rid=5515006&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4763%3Frss%3D1 Conclusion BCSS was not significantly different between the SBBC cases and their high-risk matches. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515006 Fri, 16 Dec 2011 05:00:00 +0100 5515006 Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer [Breast Cancer] http://www.medworm.com/index.php?rid=5515005&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4755%3Frss%3D1 Conclusion The results do not support the hypothesis that SCPs are beneficial for improving patient-reported outcomes. Transferring follow-up to PCPs is considered an important strategy to meet the demand for scarce oncology resources. SCPs were no better than a standard discharge visit with the oncologist to facilitate transfer. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515005 Fri, 16 Dec 2011 05:00:00 +0100 5515005 Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group [Breast Cancer] http://www.medworm.com/index.php?rid=5515004&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4748%3Frss%3D1 Conclusion GD compared with docetaxel demonstrated increased TTP in metastatic breast cancer. However, RR and OS were similar. Thus, the addition of gemcitabine failed to demonstrate any clinically meaningful benefit when combined with docetaxel. (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515004 Fri, 16 Dec 2011 05:00:00 +0100 5515004 Early Diagnosis of Hepatocellular Carcinoma by Multiple microRNAs: Validity, Efficacy, and Cost-Effectiveness [EDITORIALS] http://www.medworm.com/index.php?rid=5515003&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4745%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515003 Fri, 16 Dec 2011 05:00:00 +0100 5515003 Therapy for Pediatric Brain Tumors and the Risk of Growth Hormone Deficiency [EDITORIALS] http://www.medworm.com/index.php?rid=5515002&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4743%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515002 Fri, 16 Dec 2011 05:00:00 +0100 5515002 The Care People Need and the Education of Physicians [EDITORIALS] http://www.medworm.com/index.php?rid=5515001&cid=s_31124_6_f&fid=31124&url=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fshort%2F29%2F36%2F4742%3Frss%3D1 (Source: Journal of Clinical Oncology) Journal of Clinical Oncology journals http://www.medworm.com/rss/comments.php?id=5515001 Fri, 16 Dec 2011 05:00:00 +0100 5515001